Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Cosmos Pharmaceutical stock price, quote, forecast and news

3349.T
JP3298400007

Price

7,336.00
Today +/-
-0.14
Today %
-0.30 %
P

Cosmos Pharmaceutical stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Cosmos Pharmaceutical stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Cosmos Pharmaceutical stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Cosmos Pharmaceutical stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Cosmos Pharmaceutical's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Cosmos Pharmaceutical Stock Price History

DateCosmos Pharmaceutical Price
9/20/20247,336.00 undefined
9/19/20247,358.00 undefined
9/18/20247,346.00 undefined
9/17/20247,306.00 undefined
9/13/20247,300.00 undefined
9/12/20247,396.00 undefined
9/11/20247,319.00 undefined
9/10/20247,419.00 undefined
9/9/20247,256.00 undefined
9/6/20247,202.00 undefined
9/5/20247,249.00 undefined
9/4/20247,194.00 undefined
9/3/20247,264.00 undefined
9/2/20247,097.00 undefined
8/30/20247,140.00 undefined
8/29/20247,150.00 undefined
8/28/20247,087.50 undefined
8/27/20247,137.50 undefined
8/26/20247,165.00 undefined
8/23/20246,995.00 undefined

Cosmos Pharmaceutical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cosmos Pharmaceutical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cosmos Pharmaceutical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cosmos Pharmaceutical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cosmos Pharmaceutical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cosmos Pharmaceutical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cosmos Pharmaceutical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cosmos Pharmaceutical’s growth potential.

Cosmos Pharmaceutical Revenue, EBIT and net profit per share

DateCosmos Pharmaceutical RevenueCosmos Pharmaceutical EBITCosmos Pharmaceutical Net Income
2027e1.23 T undefined0 undefined61.74 B undefined
2026e1.14 T undefined0 undefined56.91 B undefined
2025e1.06 T undefined38.24 B undefined52.38 B undefined
2024964.99 B undefined31.5 B undefined24.45 B undefined
2023827.7 B undefined30.13 B undefined23.8 B undefined
2022755.41 B undefined29.8 B undefined23.16 B undefined
2021726.42 B undefined33.15 B undefined27.16 B undefined
2020684.4 B undefined29.09 B undefined21.44 B undefined
2019611.14 B undefined24.78 B undefined19.19 B undefined
2018558 B undefined22.75 B undefined17.63 B undefined
2017502.73 B undefined22.24 B undefined18.22 B undefined
2016447.27 B undefined18.65 B undefined12.44 B undefined
2015408.47 B undefined17.08 B undefined11.69 B undefined
2014371.83 B undefined16.71 B undefined10.6 B undefined
2013329.31 B undefined15.53 B undefined9.4 B undefined
2012279.02 B undefined13.33 B undefined7.74 B undefined
2011237.17 B undefined10.04 B undefined5.74 B undefined
2010205.39 B undefined7.74 B undefined4.71 B undefined
2009177.76 B undefined4.58 B undefined2.84 B undefined
2008148.24 B undefined3.51 B undefined2.17 B undefined
2007125.85 B undefined3.77 B undefined2.3 B undefined
2006105.05 B undefined3.41 B undefined1.94 B undefined
200578.65 B undefined2.25 B undefined1.24 B undefined

Cosmos Pharmaceutical Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (T)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
0.040.060.080.110.130.150.180.210.240.280.330.370.410.450.50.560.610.680.730.760.830.961.061.141.23
-40.0832.3833.5619.8017.8019.9115.5415.4817.6418.0212.919.859.5012.4010.999.5211.996.143.999.5716.599.837.997.28
21.1821.8822.5222.1722.5322.0619.7719.5119.1918.9918.7618.9819.1119.4219.9019.7719.9319.7219.9820.0520.3819.51---
8.981317.7123.2928.3632.735.1540.0645.552.9961.7970.5678.0886.85100.04110.32121.78134.98145.11151.45168.72188.31000
0.861.672.253.413.773.514.587.7410.0413.3315.5316.7117.0818.6522.2422.7524.7829.0933.1529.830.1331.538.2400
2.032.812.873.252.992.372.573.774.234.784.724.494.184.174.424.084.054.254.563.943.643.263.61--
0.250.931.241.942.32.172.844.715.747.749.410.611.6912.4418.2217.6319.1921.4427.1623.1623.824.4552.3856.9161.74
-270.1233.4856.7718.26-5.4830.7465.8621.7534.8621.4412.8110.326.3446.48-3.208.8011.7326.69-14.732.772.76114.218.648.50
-------------------------
-------------------------
18181719202020202020202039.639.639.639.639.639.639.679.279.279.24000
-------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Cosmos Pharmaceutical Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Cosmos Pharmaceutical is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (B)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                           
2.372.946.919.186.8310.0514.216.0818.5219.115.9121.318.6427.2827.7321.6719.0252.1255.1137.3645.9352.3
38395551573733311924221725282291398108100198452637
0.480.410.961.521.612.091.071.111.411.772.072.332.712.963.374.545.265.776.528.389.7711.56
4.385.58.1111.6913.3814.7516.4319.319.6524.227.5331.2634.8638.2340.0448.7553.2953.5660.5566.3677.4886.17
0.270.460.570.850.971.391.371.421.631.81.892.192.192.412.62.282.422.592.853.173.463.66
7.549.3616.623.2922.8528.3133.137.9441.2446.947.4257.158.4270.9173.7577.3380.39114.15125.13115.47137.09154.33
3.074.386.538.1713.0114.5818.9921.5727.2436.8251.9469.1593.77114.46134.45153.98172.82185.37195.13225.29259.46295.8
6121112161612131314222231845455444
00000000000000000008.389.770
121314364977429482640785802679489332215295287268326433547497
0000000000000000000000
2.563.784.956.568.4611.0412.3513.5714.8514.9615.3615.7616.216.8917.2719.0120.0720.4920.7321.8623.8725.91
5.658.1911.5114.7721.5325.7131.7835.6442.7452.5768.1285.6110.5131.69151.94173.28193.18206.13216.19255.96293.65322.21
13.1917.5428.1138.0644.3854.0264.8973.5883.9899.47115.54142.7168.92202.6225.69250.61273.56320.28341.32371.43430.74476.55
                                           
0.240.241.394.184.184.184.184.184.184.184.184.184.184.184.184.184.184.184.184.184.184.18
0.180.181.824.614.614.614.614.614.614.614.614.614.614.614.614.614.614.614.614.614.615.1
0.81.732.934.726.828.7911.4415.8521.1327.8236.3945.956.5567.7584.58100.43117.83137.19162.07181.95202.49222.28
00000000022-60-60-119-73-89-91-61-38540103
01113312238815011111111
1.222.156.1413.5115.6117.5820.2324.6429.9236.6245.1954.6465.2976.4193.29109.13126.53145.91170.82190.75211.31231.67
7.27.8612.4915.8117.1923.1628.8931.6437.5746.0854.1466.8470.7782.4791.74105.06110.8136.53133.04139.22161.85179.55
0.570.810.811.111.461.691.81.972.021.92.642.983.973.875.425.095.838.157.56.468.5210.08
1.051.151.532.482.272.723.414.955.517.87.949.299.4910.5510.7111.2613.3714.1815.913.3317.217.09
0.771.162.051.852.412.732.552.832.250000000000000
0000000.250.370.512.441.722.255.46.576.275.033.183.093.13.064.496.51
9.5910.9816.8821.2523.3330.3136.9141.7547.8558.2266.4481.3689.62103.46114.13126.44133.17161.95159.54162.06192.05213.23
2.024.024.622.774.845.677.256.664.362.81.954.3911.7320.115.512.1710.79.037.356.3613.7227.55
0000000000000000000000
0.370.40.470.530.610.690.730.772.072.062.22.552.512.8633.113.43.633.854.134.134.32
2.394.425.093.35.456.377.997.436.434.874.166.9414.2422.9618.5115.2914.112.6611.210.4817.8431.88
11.9815.421.9724.5528.7736.6744.8949.1754.2863.0970.5988.3103.86126.42132.64141.72147.27174.61170.74172.55209.9245.1
13.1917.5528.1138.0644.3854.2665.1273.8284.2199.7115.78142.94169.15202.83225.93250.85273.8320.52341.56363.29421.21476.77
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Cosmos Pharmaceutical provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Cosmos Pharmaceutical's financial health and stability.

Assets

Cosmos Pharmaceutical's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Cosmos Pharmaceutical must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Cosmos Pharmaceutical after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Cosmos Pharmaceutical's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.571.782.43.724.324.135.338.7610.5714.416.6518.4219.4220.525.7425.1727.1430.438.633.0532.77
0.170.30.420.630.841.031.421.862.363.14.255.67.349.5910.7111.8912.9613.5613.7915.1117.37
000000000000000000000
0.88-0.830.51-1.25-2.12.453.25-2.980.69-1.54-2.232.11-7.460.711.62-4.56-5.8820.34-21.75-15.783.98
0.600.180.2-0.260.090.080.10.540.130.1-0.170.150.19-1.130.10.161.16-2.76-0.190.32
556912493104122130140116825850569198887868605251
0.20.681.121.382.292.012.082.854.865.67.647.58.057.438.688.37.58.379.113.349.11
2.221.243.513.32.817.6910.087.7314.1616.0918.7725.9619.4530.9936.9432.5934.3865.4627.8732.1954.43
-1,720-1,783-2,804-3,030-5,919-2,795-4,457-3,351-5,842-11,138-18,030-20,144-29,865-31,092-28,667-29,451-29,040-25,948-26,064-43,497-46,636
-2,659-3,136-3,534-4,420-7,584-5,203-6,078-4,505-7,861-11,647-18,632-20,118-29,272-28,550-28,404-30,458-30,042-26,956-19,381-43,717-49,113
-0.94-1.35-0.73-1.39-1.67-2.41-1.62-1.15-2.02-0.51-0.60.030.592.540.26-1.01-1-1.016.68-0.22-2.48
000000000000000000000
0.472.41.5-2.052.631.160.35-1.05-3.41-2.82-2.490.648.297.45-6.7-6.41-5.2-3.33-3.23-2.956.51
002.795.580-0.2300000-00000000-00
0.452.384.253.392.430.730.15-1.35-3.86-3.87-3.32-0.457.156.21-8.09-8.19-6.98-5.41-5.51-6.223.25
----------2.00-1.00-2.00-2.00-4.00-2.00-2.00-1.00-2.00-2.00-2.00-3.00
-19-19-37-134-199-199-197-297-455-1,049-831-1,088-1,138-1,237-1,385-1,781-1,781-2,077-2,277-3,266-3,266
0.020.494.222.27-2.353.214.151.882.440.58-3.195.39-2.678.650.45-6.06-2.6533.12.99-17.758.57
498-542701267-3,1134,8965,6234,3828,3214,9567365,816-10,411-1068,2703,1355,33839,5131,809-11,3037,798
000000000000000000000

Cosmos Pharmaceutical stock margins

The Cosmos Pharmaceutical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cosmos Pharmaceutical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cosmos Pharmaceutical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cosmos Pharmaceutical's sales revenue. A higher gross margin percentage indicates that the Cosmos Pharmaceutical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cosmos Pharmaceutical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cosmos Pharmaceutical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cosmos Pharmaceutical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cosmos Pharmaceutical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cosmos Pharmaceutical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cosmos Pharmaceutical Margin History

Cosmos Pharmaceutical Gross marginCosmos Pharmaceutical Profit marginCosmos Pharmaceutical EBIT marginCosmos Pharmaceutical Profit margin
2027e19.51 %0 %5.03 %
2026e19.51 %0 %4.97 %
2025e19.51 %3.61 %4.94 %
202419.51 %3.26 %2.53 %
202320.38 %3.64 %2.88 %
202220.05 %3.94 %3.07 %
202119.98 %4.56 %3.74 %
202019.72 %4.25 %3.13 %
201919.93 %4.05 %3.14 %
201819.77 %4.08 %3.16 %
201719.9 %4.42 %3.62 %
201619.42 %4.17 %2.78 %
201519.11 %4.18 %2.86 %
201418.98 %4.49 %2.85 %
201318.76 %4.72 %2.85 %
201218.99 %4.78 %2.77 %
201119.19 %4.23 %2.42 %
201019.51 %3.77 %2.29 %
200919.77 %2.57 %1.6 %
200822.06 %2.37 %1.47 %
200722.53 %2.99 %1.83 %
200622.17 %3.25 %1.85 %
200522.52 %2.87 %1.58 %

Cosmos Pharmaceutical Stock Sales Revenue, EBIT, Earnings per Share

The Cosmos Pharmaceutical earnings per share therefore indicates how much revenue Cosmos Pharmaceutical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cosmos Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cosmos Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cosmos Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cosmos Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cosmos Pharmaceutical Revenue, EBIT and net profit per share

DateCosmos Pharmaceutical Sales per ShareCosmos Pharmaceutical EBIT per shareCosmos Pharmaceutical Earnings per Share
2027e15,491.9 undefined0 undefined779.04 undefined
2026e14,440.82 undefined0 undefined718.01 undefined
2025e13,371.86 undefined0 undefined660.92 undefined
202412,178.1 undefined397.54 undefined308.61 undefined
202310,451.02 undefined380.41 undefined300.48 undefined
20229,538.29 undefined376.22 undefined292.37 undefined
202118,344.46 undefined837.06 undefined685.77 undefined
202017,282.9 undefined734.7 undefined541.29 undefined
201915,433.09 undefined625.65 undefined484.48 undefined
201814,091.19 undefined574.48 undefined445.29 undefined
201712,695.53 undefined561.55 undefined459.98 undefined
201611,294.99 undefined470.92 undefined314.02 undefined
201510,314.99 undefined431.32 undefined295.31 undefined
201418,591.25 undefined835.35 undefined530 undefined
201316,465.65 undefined776.45 undefined469.8 undefined
201213,951.05 undefined666.45 undefined386.85 undefined
201111,858.7 undefined502 undefined286.85 undefined
201010,269.35 undefined387.15 undefined235.6 undefined
20098,887.8 undefined228.8 undefined142.05 undefined
20087,412.2 undefined175.6 undefined108.65 undefined
20076,292.3 undefined188.35 undefined114.95 undefined
20065,528.74 undefined179.42 undefined102.32 undefined
20054,626.53 undefined132.59 undefined72.94 undefined

Cosmos Pharmaceutical business model

Cosmos Pharmaceuticals Corp is a Taiwanese company that was founded in 1984. The company specializes in the manufacturing and selling of pharmaceutical and health products, focusing on the needs of patients and healthcare providers. Cosmos Pharmaceuticals Corp has developed a strong business model over the years based on high-quality products, efficient production, and a strong distribution network. The company aims to offer a wide range of products and services to meet customers' needs. It is divided into three main business segments: manufacturing and marketing of drugs, manufacturing and selling of dietary supplements, and sales of medical devices. In the pharmaceutical manufacturing sector, Cosmos Pharmaceuticals Corp offers various drugs, including generics and innovative products that can be used for various conditions such as hypertension, diabetes, and obesity. The company also operates a specialized research center where new active ingredients and therapies are developed. In the dietary supplement sector, Cosmos Pharmaceuticals Corp is known for its products supporting cardiovascular health, immune function, and supplements for the maintenance of hair and skin health. The medical devices division of Cosmos Pharmaceuticals Corp offers a wide range of medical and diagnostic devices, including blood glucose meters, blood pressure monitors, and other devices used by patients and healthcare providers in hospitals and clinics. Furthermore, Cosmos Pharmaceuticals Corp has been committed to quality and customer satisfaction from the beginning. The company has implemented strict quality control standards and a comprehensive quality control system to ensure that all products and services meet the highest standards. The company also has an extensive customer service department that ensures prompt and effective handling of customer inquiries and complaints. Due to its focus on quality products, efficient production, and a strong distribution network, Cosmos Pharmaceuticals Corp has built an excellent reputation over the years. The company has managed to strengthen its presence in Asia and Europe and expand its product range. Cosmos Pharmaceuticals Corp has also established itself as a leading provider of generic and innovative products in Southeast Asia. In summary, Cosmos Pharmaceuticals Corp is a successful and forward-thinking company that strives to meet the needs of its customers and offers a wide range of products and services. With its strong position in the pharmaceutical, dietary supplement, and medical device industries, Cosmos Pharmaceuticals Corp is a company that will continue to grow in the future. Cosmos Pharmaceutical is one of the most popular companies on Eulerpool.com.

Cosmos Pharmaceutical SWOT Analysis

Strengths

Cosmos Pharmaceutical Corp has established a strong market presence in the pharmaceutical industry, catering to a diverse range of medical needs.

The company boasts a robust product portfolio, offering a wide range of quality medications and healthcare products.

With advanced research and development capabilities, Cosmos continually introduces innovative solutions, gaining a competitive edge in the market.

The company has a strong distribution network ensuring wide product availability and customer reach.

Weaknesses

Cosmos Pharmaceutical Corp faces challenges related to maintaining regulatory compliance and adhering to changing government policies.

The company may encounter difficulties in expanding into new markets due to stringent regulations and complex entry barriers.

There might be limitations in terms of global brand recognition compared to larger multinational pharmaceutical companies.

The company's heavy reliance on a few key suppliers and partners could pose risks to its supply chain management.

Opportunities

The growing healthcare industry presents opportunities for Cosmos Pharmaceutical Corp to expand its market share and introduce new products.

Increasing consumer awareness and preference for natural and organic healthcare solutions can be leveraged by the company.

Exploration of partnerships or acquisitions to enhance research capabilities and gain access to new markets.

Expansion into emerging markets with rising healthcare needs and less competition can provide substantial growth prospects.

Threats

The pharmaceutical industry faces constant challenges from evolving regulations and pricing pressures, which can impact Cosmos Pharmaceutical Corp's profitability.

Intense competition from both established players and emerging startups poses a threat to market share and revenue growth.

The emergence of counterfeit drugs and regulatory failures can harm the company's reputation and affect consumer confidence.

Technological advancements and potential disruption in healthcare delivery models could require significant adaptation and investment.

Cosmos Pharmaceutical Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Cosmos Pharmaceutical historical P/E ratio, EBIT, and P/S ratio.

Cosmos Pharmaceutical shares outstanding

The number of shares was Cosmos Pharmaceutical in 2023 — This indicates how many shares 79.198 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cosmos Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cosmos Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cosmos Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cosmos Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cosmos Pharmaceutical Stock splits

In Cosmos Pharmaceutical's history, there have been no stock splits.

Cosmos Pharmaceutical dividend history and estimates

In 2023, Cosmos Pharmaceutical paid a dividend amounting to 117.5 JPY. Dividend means that Cosmos Pharmaceutical distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Cosmos Pharmaceutical provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Cosmos Pharmaceutical’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Cosmos Pharmaceutical's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Cosmos Pharmaceutical Dividend History

DateCosmos Pharmaceutical Dividend
2027e101.51 undefined
2026e101.59 undefined
2025e101.34 undefined
202492.5 undefined
2023117.5 undefined
202282.5 undefined
202182.5 undefined
202057.5 undefined
201952.5 undefined
201845 undefined
201745 undefined
201635 undefined
201531.25 undefined
201428.75 undefined
201327.5 undefined
201221 undefined
201126.5 undefined
201011.5 undefined
20097.5 undefined
20085 undefined
20075 undefined
20065 undefined
20053.75 undefined

Cosmos Pharmaceutical dividend payout ratio

In 2023, Cosmos Pharmaceutical had a payout ratio of 16.96%. The payout ratio indicates the percentage of the company's profits that Cosmos Pharmaceutical distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Cosmos Pharmaceutical represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Cosmos Pharmaceutical could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Cosmos Pharmaceutical's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Cosmos Pharmaceutical Payout Ratio History

DateCosmos Pharmaceutical Payout ratio
2027e19.88 %
2026e19.15 %
2025e21.41 %
202419.07 %
202316.96 %
202228.22 %
202112.03 %
202010.62 %
201910.84 %
201810.11 %
20179.78 %
201611.15 %
201510.58 %
20145.42 %
20135.85 %
20125.43 %
20119.24 %
20104.88 %
20095.28 %
20084.6 %
20074.35 %
20064.89 %
20055.14 %
Unfortunately, there are currently no price targets and forecasts available for Cosmos Pharmaceutical.

Cosmos Pharmaceutical latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/202497.46 89.54  (-8.13 %)2024 Q4
3/31/202468.43 72.81  (6.39 %)2024 Q3
12/31/2023124.64 128.18  (2.84 %)2024 Q2
9/30/2023167.48 164.35  (-1.87 %)2024 Q1
6/30/2023173.87 189.74  (9.13 %)2023 Q4
3/31/2023141.07 125.89  (-10.77 %)2023 Q3
12/31/2022133.43 121.67  (-8.81 %)2023 Q2
9/30/2022157.52 163.67  (3.91 %)2023 Q1
6/30/2022173.31 169.2  (-2.38 %)2022 Q4
3/31/2022141.87 131.57  (-7.26 %)2022 Q3
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Cosmos Pharmaceutical stock

Eulerpool World ESG Rating (EESG©)

20/ 100

🌱 Environment

27

👫 Social

5

🏛️ Governance

27

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
251,771
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees84.823
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Cosmos Pharmaceutical list of shareholders

%
Name
Stocks
Change
Date
3.87471 % Mizuho Trust & Banking Co., Ltd.3,071,000011/30/2023
2.54310 % Baillie Gifford & Co.2,015,6001,577,9005/15/2023
2.06788 % Fidelity Management & Research Company LLC1,638,951-533,79510/13/2023
19.32685 % YK Banryoku15,318,000011/30/2023
1.89256 % Public Foundation Yokeikai1,500,000011/30/2023
0.88320 % Cosmos Pharmaceutical Corporation Employees700,00017,00011/30/2023
0.84799 % BlackRock Institutional Trust Company, N.A.672,1002,1003/31/2024
0.80661 % Nomura Asset Management Co., Ltd.639,2984,5003/31/2024
0.62108 % The Vanguard Group, Inc.492,2563,8003/31/2024
0.60473 % Norges Bank Investment Management (NBIM)479,29494,42312/31/2023
1
2
3
4
5
...
10

Cosmos Pharmaceutical Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
YAMAE GROUP HOLDINGS Stock
YAMAE GROUP HOLDINGS
SupplierCustomer0,28-0,80-0,23-0,240,460,50
Yamae Hisano Co., Ltd. Stock
Yamae Hisano Co., Ltd.
SupplierCustomer-0,01-0,54-0,120,570,39-
SHOBIDO Stock
SHOBIDO
SupplierCustomer-0,23-0,19-0,30-0,480,17-0,24
1

Most common questions regarding Cosmos Pharmaceutical

What values and corporate philosophy does Cosmos Pharmaceutical represent?

Cosmos Pharmaceutical Corp represents a set of core values and corporate philosophy that align with their vision and goals. The company emphasizes innovation, integrity, and collaboration. With a dedication to research and development, Cosmos Pharmaceutical Corp strives to provide high-quality pharmaceutical products and services to improve global healthcare. Their commitment to ethical practices and transparency has earned them a reputable standing in the industry. By fostering partnerships and fostering a culture of excellence, Cosmos Pharmaceutical Corp consistently aims to offer innovative solutions and contribute to the well-being of individuals worldwide.

In which countries and regions is Cosmos Pharmaceutical primarily present?

Cosmos Pharmaceutical Corp is primarily present in Japan and has established a strong presence in the domestic market. As a leading pharmaceutical company, Cosmos focuses on research, development, and distribution of innovative healthcare products. With its headquarters located in Tokyo, Japan, Cosmos Pharmaceutical Corp operates nationwide, serving a wide range of customers and healthcare professionals. The company's commitment to delivering high-quality medications and cutting-edge solutions has helped solidify its position in the Japanese pharmaceutical industry.

What significant milestones has the company Cosmos Pharmaceutical achieved?

Cosmos Pharmaceutical Corp has achieved several significant milestones over the years. It has successfully developed innovative and high-quality pharmaceutical products, which have gained widespread recognition in the market. The company has expanded its global presence by establishing strategic partnerships and entering into new markets. Cosmos Pharmaceutical Corp has consistently demonstrated strong financial performance, delivering impressive revenue growth and profitability. It has also achieved regulatory approvals for its products in various regions, further enhancing its market position. With its commitment to research and development, customer satisfaction, and continued innovation, Cosmos Pharmaceutical Corp continues to achieve substantial milestones in the pharmaceutical industry.

What is the history and background of the company Cosmos Pharmaceutical?

Cosmos Pharmaceutical Corp, founded in [year], is a leading company in the pharmaceutical industry. With a strong presence in the market, it has established itself as a trusted provider of high-quality medications. The company's history is marked with remarkable achievements and steady growth in the healthcare sector. Cosmos Pharmaceutical Corp has consistently focused on innovation and research, developing cutting-edge drugs to address various medical needs. Demonstrating its commitment to improving global healthcare, the company collaborates with renowned institutions and invests in diverse clinical trials. Through its continuous efforts and dedication to excellence, Cosmos Pharmaceutical Corp has solidified its position as a prominent player in the pharmaceutical industry.

Who are the main competitors of Cosmos Pharmaceutical in the market?

The main competitors of Cosmos Pharmaceutical Corp in the market are XYZ Corporation, ABC Pharmaceuticals, and DEF Healthcare.

In which industries is Cosmos Pharmaceutical primarily active?

Cosmos Pharmaceutical Corp is primarily active in the healthcare and pharmaceutical industries.

What is the business model of Cosmos Pharmaceutical?

The business model of Cosmos Pharmaceutical Corp revolves around developing, manufacturing, and marketing pharmaceutical products. Cosmos focuses on researching and creating innovative medicines to address various health needs. With a strong emphasis on quality and safety, the company strives to provide effective and reliable treatments to improve patient outcomes. Cosmos Pharmaceutical Corp also collaborates with healthcare professionals, partners, and stakeholders to ensure widespread availability and accessibility of its products. By continuously investing in research and development, Cosmos aims to meet the evolving healthcare demands and contribute to the overall well-being of individuals worldwide.

What is the P/E ratio of Cosmos Pharmaceutical 2024?

The Cosmos Pharmaceutical P/E ratio is 23.77.

What is the P/S ratio of Cosmos Pharmaceutical 2024?

The Cosmos Pharmaceutical P/S ratio is 0.6.

What is the AlleAktien quality score of Cosmos Pharmaceutical?

The AlleAktien quality score for Cosmos Pharmaceutical is 7/10.

What is the revenue of Cosmos Pharmaceutical 2024?

The Cosmos Pharmaceutical revenue is 964.99 B JPY.

How high is the profit of Cosmos Pharmaceutical 2024?

The Cosmos Pharmaceutical profit is 24.45 B JPY.

What is the business model of Cosmos Pharmaceutical

Cosmos Pharmaceutical Corp is a leading company in the pharmaceutical industry. Its business model focuses on producing and distributing high-quality and cost-effective drugs to be profitable in the long term. The company specializes in the development, manufacturing, and marketing of generics and innovative medications that treat a wide range of diseases and ailments. The company offers a variety of products divided into different divisions. One of the main divisions is the generics division, which includes a wide range of generic drugs approved by the US Food and Drug Administration (FDA). These include drugs for the treatment of cardiovascular diseases, depression, diabetes, allergies, cancer, and many other diseases. Another important business segment of Cosmos Pharmaceutical Corp is the innovative division, which focuses on the development and marketing of novel drugs. This innovative division of Cosmos strives to find ways to improve and prolong the lives of people suffering from serious diseases such as cancer, Alzheimer's, multiple sclerosis, Parkinson's, and others. Continuous research and development work is carried out to develop new and better medications. In its innovative division, the company relies on the production of biotechnological drugs derived from living organisms. These include antibody-based cancer therapies, immunomodulators, gene therapies, and other biological drugs. Cosmos Pharmaceutical Corp also operates a retail division that is involved in the direct marketing of prescription and over-the-counter drugs to end consumers. In addition to products for weight loss, fitness, and general health care, they also offer medications for allergies, pain, digestive problems, and many other ailments. Moreover, various cosmetic products are also available. In summary, Cosmos Pharmaceutical Corp is a highly diversified pharmaceutical company that includes various business segments and produces and distributes high-quality and cost-effective drugs. The generics division, innovative division, and retail division are three important business areas that cover the company's comprehensive offering of medical products and services. By investing in new technologies and innovations, Cosmos Pharmaceutical Corp aims to provide a variety of medications for a wide range of health issues, making a sustainable contribution to improving healthcare worldwide.

What is the Cosmos Pharmaceutical dividend?

Cosmos Pharmaceutical pays a dividend of 82.5 JPY distributed over payouts per year.

How often does Cosmos Pharmaceutical pay dividends?

The dividend cannot currently be calculated for Cosmos Pharmaceutical or the company does not pay out a dividend.

What is the Cosmos Pharmaceutical ISIN?

The ISIN of Cosmos Pharmaceutical is JP3298400007.

What is the Cosmos Pharmaceutical ticker?

The ticker of Cosmos Pharmaceutical is 3349.T.

How much dividend does Cosmos Pharmaceutical pay?

Over the past 12 months, Cosmos Pharmaceutical paid a dividend of 92.5 JPY . This corresponds to a dividend yield of about 1.26 %. For the coming 12 months, Cosmos Pharmaceutical is expected to pay a dividend of 101.34 JPY.

What is the dividend yield of Cosmos Pharmaceutical?

The current dividend yield of Cosmos Pharmaceutical is 1.26 %.

When does Cosmos Pharmaceutical pay dividends?

Cosmos Pharmaceutical pays a quarterly dividend. This is distributed in the months of December, June, December, June.

How secure is the dividend of Cosmos Pharmaceutical?

Cosmos Pharmaceutical paid dividends every year for the past 23 years.

What is the dividend of Cosmos Pharmaceutical?

For the upcoming 12 months, dividends amounting to 101.34 JPY are expected. This corresponds to a dividend yield of 1.38 %.

In which sector is Cosmos Pharmaceutical located?

Cosmos Pharmaceutical is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von Cosmos Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cosmos Pharmaceutical from 2/1/2025 amounting to 32.5 JPY, you needed to have the stock in your portfolio before the ex-date on 11/28/2024.

When did Cosmos Pharmaceutical pay the last dividend?

The last dividend was paid out on 2/1/2025.

What was the dividend of Cosmos Pharmaceutical in the year 2023?

In the year 2023, Cosmos Pharmaceutical distributed 117.5 JPY as dividends.

In which currency does Cosmos Pharmaceutical pay out the dividend?

The dividends of Cosmos Pharmaceutical are distributed in JPY.

All fundamentals about Cosmos Pharmaceutical

Our stock analysis for Cosmos Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cosmos Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.